Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
Public Policy: Federal Policy Priorities 2014
Share |

2014 FEDERAL POLICY PRIORITIES

 
Washington’s Life Sciences - One of Washington State’s Strongest Economic Drivers

Washington state is fortunate to have a dynamic, diverse and growing statewide life sciences sector. Between 2007 and 2012, life science jobs grew 10 percent. while the rest of the private sector grew zero perecnet. The fifth largest sector in the state, the life sciences employ 34,000 direct jobs and 91,000 total jobs. The life sciences industry is the State’s fifth largest employer. Federal officials must actively work to create and ensure a supportive environment that enables entrepreneurial people and companies to convert innovative ideas into marketable new products, services and jobs.

Funding for Basic Research

Recommendation: Support funding of the National Institutes of Health.

 

The National Institutes of Health’s (NIH) current federal funding of $32 billion sustains its mission of improving health through medical science breakthroughs. The NIH makes possible the United States’ international leadership in science and biomedical research. The NIH also is a pillar of the nation’s economic recovery. Locally, robust NIH funded biomedical research contributes substantially to the Washington state economy—alone NIH grants to University of Washington School of Medicine faculty exceeded $700 million in FY 2010.

Medical Device Excise Tax

Recommendation: continue to work with partners AdvaMed and MDMA to have the excise tax repealed.

 

The ACA introduced a medical device excise tax. While negotiations during 2010 year improved the tax, we continue to work with partner organizations MDMA and AdvaMed to get the tax repealed. There are more than 180 members of the House who have signed on in support of the repeal

Reimbursement

Recommendation: Continue to work with Bio and other partners so that reimbursement policy does not compromise patient access to innovative products and therapies designed to provide answers for unmet medical needs.

 

This is an issue that will have a number of inflection points as policies are developed in response to debt reduction and implementation of the Affordable Care Act. The issue is likely to be more active at the federal level, than the state level.

 

For more information contact:

Chris Rivera, President, 206-456-9567 or chris@washbio.org
Patti Tenney, Senior Director of Public Affairs, 206-456-9566 or patti@washbio.org

more WBBA Calendar

12/2/2014
ETI- Failure Mode and Effects Analysis (Design & Development)

12/3/2014
Got Investigational New Drug Questions? Secrets to Successful INDs & Virtual Development Teams

Featured Partners
Business WireOn behalf of thousands of company and organizational clients, Business Wire transmits full-text news

Membership Management Software Powered by YourMembership.com®  ::  Legal